Disease‐linked TDP‐43 hyperphosphorylation suppresses TDP‐43 condensation and aggregation. (3rd February 2022)

• Record Type: Journal Article
• Authors: Gruijs da Silva, Lara A; Simonetti, Francesca; Hutten, Saskia; Riemenschneider, Henrick; Sternburg, Erin L; Pietrek, Lisa M; Gebel, Jakob; Dötsch, Volker; Edbauer, Dieter; Hummer, Gerhard; Stelzl, Lukas S; Dormann, Dorothee
• Is Part Of: EMBO journal. Volume 41:Number 8(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-02-03
• Subjects: neurodegeneration -- phase separation -- phosphorylation -- RNA‐binding protein -- TDP‐43; Molecular biology -- Periodicals; 572.805
• DOI: 10.15252/embj.2021108443
• Languages: English
• ISSNs: 0261-4189

Abstract

Abstract: Post‐translational modifications (PTMs) have emerged as key modulators of protein phase separation and have been linked to protein aggregation in neurodegenerative disorders. The major aggregating protein in amyotrophic lateral sclerosis and frontotemporal dementia, the RNA‐binding protein TAR DNA‐binding protein (TDP‐43), is hyperphosphorylated in disease on several C‐terminal serine residues, a process generally believed to promote TDP‐43 aggregation. Here, we however find that Casein kinase 1δ‐mediated TDP‐43 hyperphosphorylation or C‐terminal phosphomimetic mutations reduce TDP‐43 phase separation and aggregation, and instead render TDP‐43 condensates more liquid‐like and dynamic. Multi‐scale molecular dynamics simulations reveal reduced homotypic interactions of TDP‐43 low‐complexity domains through enhanced solvation of phosphomimetic residues. Cellular experiments show that phosphomimetic substitutions do not affect nuclear import or RNA regulatory functions of TDP‐43, but suppress accumulation of TDP‐43 in membrane‐less organelles and promote its solubility in neurons. We speculate that TDP‐43 hyperphosphorylation may be a protective cellular response to counteract TDP‐43 aggregation. Synopsis: C‐terminal hyperphosphorylation of TDP‐43, a pathological hallmark of several neurodegenerative disorders, enhances the liquidity of TDP‐43 condensates and suppresses TDP‐43 condensation and aggregation, shedding a new light on this TDP‐43 disease‐linked posttranslational modification. TDP‐43 phosphorylation by CK1δ or C‐terminal phosphomimetic mutations suppress TDP‐43 phase separation and aggregation. C‐terminal phosphomimetic mutations enhance liquidity and dynamics of TDP‐43 condensates. Suppression of phase separation is associated with loss of protein‐protein interactions in the C‐terminus and enhanced solvation of negatively charged groups. TDP‐43 bearing C‐terminal phosphomimetic mutations fails to condense into stress‐induced membrane‐less compartments and remains dispersed. Abstract : C‐terminal TDP‐43 hyperphosphorylation may be a protective cellular response to counteract TDP‐43 aggregation, rather than a driver of neuropathology as previously assumed.